Inhibikase Therapeutics
Presence
Inhibikase Therapeutics is a company listed under the stock ticker IKT (US).
Executives
View the org chart displaying its 9 main executives
Most searched biographies at Inhibikase Therapeutics
- Milton Werner, Director, President and Chief Executive Officer
- Roy Freeman, Director
- Dennis Berman, Director
Popular executive movements at Inhibikase Therapeutics
- Joseph Frattaroli, Chief Financial Officer, will retire on Mar. 31, 2024 (posted on January 17 2024).
- Garth Lees-Rolfe who is Vice President of Finance, will be promoted to Chief Financial Officer on Mar. 31, 2024 (posted on January 17 2024).
Create your alert
to follow the executive moves at Inhibikase Therapeutics.
Biotechnology
Inhibikase Therapeutics has 2,281 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Inhibikase Therapeutics
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
- Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
- Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
- Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
- Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
- Press Releases
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
- View more press releases Close
Social media about Inhibikase Therapeutics
- Inhibikase Therapeutics on Wikipedia, Google News & Yahoo Finance
- Inhibikase Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Dennis Berman 
Call Inhibikase Therapeutics at +1 678...
